COPD Management Strategies

Assessment and Classification

• The American Thoracic Society recommends COPD assessment should separate spirometric evaluation from symptom evaluation, with ABCD groups derived from patient symptoms and history of exacerbations 1
• Patients should be classified into Groups A-D based on symptom burden and exacerbation risk to guide appropriate treatment selection, as recommended by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 1

Pharmacologic Management

• The Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends that Group A patients start with a bronchodilator (short-acting or long-acting) 1
• For Group B patients, the GOLD guidelines suggest beginning with a long-acting bronchodilator (LAMA or LABA); escalate to LAMA+LABA if symptoms persist 1
• The GOLD guidelines recommend that Group C patients start with a LAMA; consider LAMA+LABA or LABA+ICS if exacerbations continue 1
• For Group D patients, the GOLD guidelines suggest beginning with LAMA or LAMA+LABA; consider triple therapy (LAMA+LABA+ICS) for persistent symptoms/exacerbations 1
• The American College of Chest Physicians recommends Bronchodilators as first-line therapy for symptom relief and improved airflow 1, 2
• The European Respiratory Society suggests using Short-acting β2-agonists and anticholinergics for immediate symptom relief 3
• The Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends using Long-acting bronchodilators (LABAs and LAMAs) for maintenance therapy 1
• The American Thoracic Society recommends Combination therapy (LAMA+LABA) for better outcomes than either agent alone 1
• The Global Initiative for Chronic Obstructive Lung Disease (GOLD) suggests considering Inhaled Corticosteroids (ICS) in addition to bronchodilator therapy for patients with frequent exacerbations 1
• The European Respiratory Society recommends using a large-volume spacer or dry-powder system for high doses (≥1,000 μg/day) of ICS 3
• The American College of Chest Physicians recommends monitoring for increased pneumonia risk with ICS therapy 4

Management of Exacerbations

• The European Respiratory Society recommends Antibiotics when bacterial infection is suspected in mild exacerbations 5
• The European Respiratory Society suggests increasing dose/frequency or combining β2-agonists and anticholinergics for mild exacerbations 5
• The European Respiratory Society recommends controlled oxygen therapy for severe exacerbations 5
• The European Respiratory Society suggests using air-driven nebulizers with supplemental oxygen by nasal cannulae for severe exacerbations 6
• The European Respiratory Society recommends administering systemic corticosteroids (oral or IV) for severe exacerbations 6
• The European Respiratory Society suggests providing antibiotics (oral or IV) when indicated for severe exacerbations 6

Non-Pharmacologic Management

• The American Thoracic Society recommends Pulmonary Rehabilitation for patients with high symptom burden and risk of exacerbations (Groups B, C, and D) 1
• The American College of Chest Physicians recommends including a combination of constant load or interval training with strength training in pulmonary rehabilitation 1
• The Global Initiative for Chronic Obstructive Lung Disease (GOLD) suggests providing nutritional supplementation for malnourished patients 1
• The European Respiratory Society recommends aiming for ideal body weight and avoiding high-carbohydrate diets and extremely high caloric intake 7
• The American College of Chest Physicians recommends administering influenza vaccination annually to all COPD patients 1
• The American College of Chest Physicians recommends providing pneumococcal vaccinations (PCV13 and PPSV23) for patients ≥65 years and younger patients with significant comorbidities 1

Oxygen Therapy

• The American Thoracic Society recommends Long-term oxygen therapy for stable patients with PaO2 ≤55 mm Hg or SaO2 ≤88% (with or without hypercapnia), confirmed twice over 3 weeks 1
• The American College of Chest Physicians recommends considering long-term oxygen therapy for patients with PaO2 between 55-60 mm Hg or SaO2 of 88% with evidence of pulmonary hypertension, peripheral edema, or polycythemia 1

Advanced Interventions

• The American Thoracic Society recommends considering Non-invasive ventilation (NIV) for patients with pronounced daytime hypercapnia and recent hospitalization 1
• The American College of Chest Physicians recommends considering Lung volume reduction surgery or bronchoscopic approaches for selected patients with heterogeneous or homogenous emphysema and significant hyperinflation 1
• The International Society for Heart and Lung Transplantation recommends considering Lung transplantation for selected patients with very severe COPD without contraindications 1

Special Considerations

• The European Respiratory Society recommends assessing risk for air travel for patients with chronic hypoxemia or borderline PaO2 (≤70 mm Hg) at rest 5
• The American College of Chest Physicians recommends regularly monitoring symptoms, exacerbations, and airflow limitation 8
• The American Thoracic Society recommends adjusting therapy as disease progresses 8
• The American College of Chest Physicians recommends evaluating symptoms that indicate worsening or development of comorbidities 8